ARS Pharmaceuticals, Inc. Income Statement
SPRY / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
ARS Pharmaceuticals, Inc. reported $84M in revenue and $171M in net loss for FY2025. Revenue has grown at a 97.8% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $30.0K | $5.5M | $5.5M | - |
| Cost of Revenue | - | - | $0 | - | - | - |
| SG&A Expense | $230.1M | $71.7M | $47.3M | $4.7M | $4.7M | $8.3M |
| R&D Expense | $13.2M | $19.6M | $20.3M | $20.3M | $20.3M | $24.6M |
| Operating Income | -$179.4M | -$3.1M | -$67.5M | -$19.5M | -$19.5M | -$32.9M |
| Interest Expense | - | - | - | - | $106.0K | -$29.0K |
| Income Tax | -$80.0K | $288.0K | $0 | $0 | $0 | $0 |
| Net Income | -$171.3M | $8.0M | -$54.4M | -$20.2M | -$20.2M | -$32.9M |
| EPS (Basic) | -$1.74 | -$0.57 | -$0.57 | -$0.70 | -$0.70 | - |
| EPS (Diluted) | -$1.74 | -$0.57 | -$0.57 | -$0.70 | -$0.70 | - |
| Shares Outstanding | 99.3M | 96.4M | 96.4M | 30.4M | 28.9M | 2.9M |
| Operating Margin | -212.9% | -3.5% | -225066.7% | -353.3% | - | - |
| Profit Margin | -203.3% | 9.0% | -181216.7% | -367.6% | - | - |